<DOC>
	<DOC>NCT00703534</DOC>
	<brief_summary>This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).</brief_summary>
	<brief_title>Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Lesogaberan</mesh_term>
	<criteria>Subject able to read and write US english and able to use electronic devices Subjects who have experienced GERD symptoms for at least six months Subjects currently taking a prescription or overthecounter PPI medications for GERD Body Mass Index (BMI) 18.535.0, inclusive Subjects that have not experienced any GERD symptoms improvement at all after PPI treatment Subjects who have any of the following conditions or diseases Heart disease, Angina, Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer Prior surgery of the upper Gastrointestinal (GI) tract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>GERD</keyword>
	<keyword>Acid Reflux</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>non-acid reflux</keyword>
	<keyword>PRO measures</keyword>
</DOC>